港股異動 | 藥明巨諾-B(2126.HK)一度大漲近8% “瑞基侖賽注射液”獲批上市
格隆匯9月3日丨藥明巨諾-B(2126.HK)高開高走,盤中一度大漲近8%,現報18.38港元,漲4.43%,暫成交2271萬港元,最新市值73.8億港元。今日,NMPA官網顯示,藥明巨諾CAR-T療法產品“瑞基侖賽注射液”(JWCAR029)獲批上市,用於經過二線或以上全身性治療後成人患者的復發或難治性大B細胞淋巴瘤。瑞基侖賽是國內第2款獲批上市的CAR-T產品,同時值得注意的是,它也是國內首個獲批的1類CAR-T 、全球第6款獲批上市的CAR-T產品。藥明巨諾是一家專注於領先細胞免疫療法的研發、轉型和推廣的臨牀階段生物製藥公司,也是國內首個獲得以CD19為靶點的CAR-T細胞(嵌合抗原受體T細胞)治療產品的IND臨牀批件的企業,領跑中國CAR-T臨牀研究。瑞銀、高盛近日紛紛發研報維持藥明巨諾“買入”評級,目標價分別為38.3港元及35.46港元。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.